CTKB earnings analysis
What we found in CTKB's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Cytek Biosciences reported Q1 2026 revenue of $44.1 million, a 6% increase year-over-year, but missed analyst expectations. The net loss more than doubled to $18.9 million, driven by higher operating expenses. Management reaffirmed its 2026 revenue guidance of $205 million to $212 million, targeting 2-5% growth for the year. The company faced an increase in general and administrative costs due to litigation and consulting expenses.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Growth Year-Over-Year
- Q1 2026 revenue increased 6% to $44.1M from $41.5M in Q1 2025.
- Increased Service Revenue
- Service revenue for Q1 2026 rose 15% to $15.4M, up from $13.3M in Q1 2025.
- Strong Cash Position
- Cash and cash equivalents at $262.2M as of March 31, 2026, slightly up from $261.5M at year-end 2025.
- Reaffirmed 2026 Revenue Guidance
- Management confirmed 2026 revenue guidance of $205M to $212M, expecting 2-5% growth.
- Operating Expense Control Efforts
- Despite a $5.6M increase in general and administrative expenses, the company is focusing on cost management.
- Increased Interest Income
- Interest income rose 55% to $787,000 in Q1 2026 from $508,000 in Q1 2025.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Continued Net Loss
- Net loss widened to $18.9M in Q1 2026 from $11.4M in Q1 2025, indicating rising operational pressures.
- High General Administrative Costs
- General and administrative expenses surged 43% to $18.5M due to litigation and consulting.
- Potential Delisting from Nasdaq
- Failure to comply with Nasdaq continued listing requirements could jeopardize the trading of the stock.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.15
- Gross margin
- 48%
- Operating margin
- -41%
- Segment
- Direct Sales: $30.3M; Distributor Sales: $13.9M
What they said about what is next.
2026 revenue guidance reaffirmed; growth of 2% to 5% expected.
The filing reads worse than the one before it.
What came before.
- 10-K · February 26, 2026
- Cytek reported fiscal 2025 revenue of $201.5 million (up $1.0 million vs. $200.5 million in 2024) while recording a materially larger GAAP net loss of $66.5 million in 2025 (vs. $6.0 million in 2024). The company…
- 10-Q · November 5, 2025
- Cytek reported quarterly revenue of $52.293M (three months ended Sept. 30, 2025) — up $0.793M (+1.5%) year-over-year from $51.500M — driven by service revenue growth but with product sales slightly down. Gross profit…
- 10-Q · May 8, 2025
- Cytek reported Q1 revenue of $41,457,000, down from $44,860,000 a year ago, with gross profit of $20,157,000 (48.6%) and an operating loss of $14,975,000. Net loss widened to $11,402,000 (EPS $(0.09)) versus $6,169,000…
- 10-Q · November 7, 2024
- Cytek reported Q3 revenue of $51.5M (up $3.5M or 7.3% vs. $48.0M a year ago) and turned a year-ago loss into net income of $0.9M (EPS $0.01 vs. $(0.05)). Gross profit was $29.0M (56.3% margin) while operating loss…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing CTKB makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever